Degenerative Joint Disease of Hip

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

I
IQVIANC - Durham
1 program
Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - EuropeN/A
P
ParexelMA - Boston
1 program
Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - EuropeN/A1 trial
Active Trials
NCT03566082Completed135Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ParexelPost-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

Clinical Trials (1)

Total enrollment: 135 patients across 1 trials

NCT03566082ParexelPost-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

Start: May 2009Est. completion: Oct 2021135 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space